Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sara Di Giusto"'
Autor:
Sara Di Giusto, Eleonora Toffoletti, Massimiliano Bonifacio, Gianni Binotto, Maria Cristina Miggiano, Elisabetta Calistri, Manuela Stulle, Anna Ermacora, Rossella Stella, Luigi Scaffidi, Fabio D'Amore, Giorgia Scotton, Davide Griguolo, Giovanna De Matteis, Roberta Bertorelle, Mauro Krampera, Gianpietro Semenzato, Renato Fanin, Daniela Damiani, Mario Tiribelli
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3180-3184 (2023)
Abstract We analyzed BCR::ABL1 expression at stop and in the first month after discontinuation in 168 chronic myeloid leukemia patients who stopped imatinib or 2nd generation tyrosine kinase inhibitors (2G‐TKIs) while in sustained deep molecular re
Externí odkaz:
https://doaj.org/article/6d9378c7422342778ca471ef994a2735
Autor:
Mario Tiribelli, Angela Michelutti, Margherita Cavallin, Sara Di Giusto, Renato Fanin, Daniela Damiani
Publikováno v:
Turkish Journal of Hematology, Vol 38, Iss 2, Pp 119-125 (2021)
Objective: CD200 and BCL2 overexpression is independently associated with inferior survival in acute myeloid leukemia (AML), and these two factors are frequently co-expressed; however, no data are available on the role of concomitant aberrant CD200 a
Externí odkaz:
https://doaj.org/article/8703e9a0d7e549e88b9ec5e0043bebed
Publikováno v:
European journal of haematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efa97ae496edb2f53910ccd95fd0d5ad
https://pubmed.ncbi.nlm.nih.gov/36458956
https://pubmed.ncbi.nlm.nih.gov/36458956
Autor:
Sara Di Giusto, Eleonora Toffoletti, Massimiliano Bonifacio, Gianni Binotto, Maria Cristina Miggiano, Elisabetta Calistri, Manuela Stulle, Anna Ermacora, Rossella Stella, Luigi Scaffidi, Fabio D'Amore, Giorgia Scotton, Davide Griguolo, Giovanna De Matteis, Roberta Bertorelle, Mauro Krampera, Gianpietro Semenzato, Renato Fanin, Daniela Damiani, Mario Tiribelli
We analyzed BCR::ABL1 expression at stop and in the first month after discontinuation in 168 chronic myeloid leukemia patients who stopped imatinib or 2nd generation tyrosine kinase inhibitors (2G-TKIs) while in sustained deep molecular response. Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f612b6db58b703a2fc6d6d69bce3536d
https://hdl.handle.net/11390/1235784
https://hdl.handle.net/11390/1235784
Autor:
Mario Tiribelli, Renato Fanin, Daniela Damiani, Sara Di Giusto, Margherita Cavallin, Angela Michelutti, Erica Simeone
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 5096, p 5096 (2021)
Journal of Clinical Medicine
Volume 10
Issue 21
Journal of Clinical Medicine
Volume 10
Issue 21
BCL-2 overexpression has been associated with resistance to chemotherapy and reduced survival in acute myeloid leukemia (AML), but few data are available in elderly patients, a subset accounting for majority of AML cases and with dismal prognosis. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52eea4d3c6101152bd09a4ac4683ac8a
https://pubmed.ncbi.nlm.nih.gov/34768616
https://pubmed.ncbi.nlm.nih.gov/34768616
Autor:
Mario Tiribelli, Antonella Geromin, Renato Fanin, Erica Simeone, Margherita Cavallin, Daniela Damiani, Sara Di Giusto
Publikováno v:
European Journal of Haematology. 99:269-274
Objective overexpression of ABCG2 and CD200 have been independently associated with poor outcome in acute myeloid leukemia (AML). However, no data are available on the role of these two factors in patients with core binding factor (CBF) positive or F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63d0b6128cfd20f2c7ac66a65603a159
https://doi.org/10.1111/ejh.12915
https://doi.org/10.1111/ejh.12915
Autor:
Gianni Binotto, Maria Cristina Miggiano, Gianpietro Semenzato, Daniela Damiani, Manuela Stulle, Eleonora Toffoletti, Renato Fanin, Mario Tiribelli, Massimiliano Bonifacio, Rossella Stella, Anna Ermacora, Mauro Krampera, Elisabetta Calistri, Fabio D'Amore, Giorgia Scotton, Luigi Scaffidi, Sara Di Giusto, Roberta Bertorelle, Giovanna De Matteis
Publikováno v:
Blood. 136:9-10
Introduction: the possibility to discontinue TKI therapy and maintaining molecular response, the so called "treatment-free remission" (TFR) has become common clinical practice and a goal of therapy in chronic myeloid leukemia (CML). It is now accepte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1af41bdfa01717a4356972e7908da8ce
https://doi.org/10.1182/blood-2020-135968
https://doi.org/10.1182/blood-2020-135968